Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 8-K

Pacira Pharmaceuticals, Inc. Form 8-K August 19, 2015

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

# CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 17, 2015

# PACIRA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction of incorporation)

**001-35060** (Commission File Number)

**51-0619477** (IRS Employer Identification No.)

5 Sylvan Way, Suite 300, Parsippany, New Jersey 07054

(Address of principal executive offices) (Zip Code)

(973) 254-3560

Registrant s telephone number, including area code

## Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any the following provisions:	∤ of
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	)
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 17, 2015, Pacira Pharmaceuticals, Inc. (the Company) appointed James B. Jones, MD, as Senior Vice President and Chief Medical Officer of the Company. Dr. Jones replaces Gary Patou, MD, as Chief Medical Officer of the Company effective August 17, 2015. Dr. Patou will remain with the Company as a clinical consultant.

### Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 8-K

#### Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pacira Pharmaceuticals, Inc.

Date: August 19, 2015 By: /s/ James Scibetta

James Scibetta

Senior Vice President, Chief Financial Officer

and Head of Technical Operations

3